Remove 2014 Remove Access Remove Clinical Trials Remove Medicine
article thumbnail

Wake Network Retains CRO Santé Cannabis to Conduct Clinical Trials in Psilocybin Therapies

Cannabis Law Report

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. This engagement will build on the strong foundation on Santé, having treated more than 10,000 patients since 2014 under a real-world data protocol.

article thumbnail

European Regulatory Lead MAPS PBC Santa Cruz, CA

Cannabis Law Report

The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. Founded in 2014, MAPS PBC is a Public Benefit Corporation that prioritizes public benefit over profit. European Regulatory Lead Executive Summary.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Press Release: MAPS is Granted Innovation Passport in United Kingdom for MDMA as an Adjunct to Therapy for PTSD

Cannabis Law Report

The designation is intended to accelerate the timeline for approval of innovative medicines for treatment of life-threatening conditions or those which present a significant patient or public health need. No drug is without risks, so clinical trials have included careful investigation of possible adverse effects.

Therapy 52
article thumbnail

MAPS – Position: European Regulatory Lead

Cannabis Law Report

The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. Founded in 2014, MAPS PBC is a Public Benefit Corporation that prioritizes public benefit over profit. European Regulatory Lead Executive Summary.

article thumbnail

8 famous people you didn’t know were cannabis patients

The Cannigma

In 2019, Stewart called on the UK government to ease the restrictions surrounding cannabis-based medicines, and said in a statement that “the moment I started using cannabis-based cream it worked and I could feel an immediate reduction in discomfort. It meant I could grip my hands and hook my thumb around the steering wheel of a car again.

Patients 107
article thumbnail

Exclusive Worldwide License Agreement with Canopy Growth Corporation for Key Pharmaceutical Assets

Cannabis Law Report

Access to Canopy Growth’s cannabinoid library including 335 derivatives and 14 patent families. Accelerated timelines to clinical trials and expansion of drug development pipeline. Phase 1 clinical trials are scheduled for Q3 2022 with Phase 2 trials expected in Q2 2023.

article thumbnail

New Frontiers in the Law of Psychedelics

Cannabis Law Report

In a typical scenario, psychedelic substances would be used in conjunction with psychotherapy sessions to treat disorders for which other medicinal therapies have failed. Beginning in 2018, the FDA has started to grant special designations to study the medicinal use of psilocybin via Breakthrough Therapy status. Id ; 21 CFR 312.1-10;

Law 81